Because disruption of Erk1 dampens osteoclast function to a degree sufficient to increase bone mineral density in vivo, an Erk1-targeted chemical kinase inhibitor may be an effective therapeutic agent for the diminished bone mineral density found in multiple skeletal pathologies, including hormonal loss-dependent osteoporosis. This evidence concerns the gene MAPK3 and osteoporosis.